Increased fibrosis progression rates in hepatitis C patients carrying the prothrombin G20210A mutation

查看全文 作　　者：Nitsan [1]Maharshak;Philippe [2]Halfon;Varda [3]Deutsch;Hava [4]Peretz;Shlomo [5]Berliner;Sigal [1]Fishman;Shira Zelber-[1]Sagi;Uri [3]Rozovski;Moshe [1]Leshno;Ran [1]Oren

机构地区：[1]Department of Gastroenterology and Liver diseases, Tel Aviv Sourasky Medical Center, aff iliated to the Sackler School of Medicine, Tel Aviv University;[2]Department of Virology, Laboratoire Alphabio, 23 Rue de Friedland, Hpital Ambroise Paré;[3]The Hematology Institute, Tel Aviv Sourasky Medical Center, affi liated to the Sackler School of Medicine, Tel Aviv University;[4]Clinical Biochemistry Laboratory, Tel Aviv Sourasky Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University;[5]Internal Medicine 'E', Tel Aviv Sourasky Medical Center, affi liated to the Sackler School of Medicine, Tel Aviv University

出　　处：《World Journal of Gastroenterology》索引2011年第17卷第45期,共7页

摘　　要：AIM: To examine whether hepatitis C virus (HCV)-infected patients who carry hypercoagulable mutationssuffer from increased rates of liver fi brosis. METHODS: We analyzed DNA samples of 168 HCV patients for three common hypercoagulable gene mutations: prothrombin 20210 (PT20210), factor V Leiden (FV Leiden) and methylene tetrahydrofolate reductase (MTHFR). The patients were consecutively recruited as part of the prospective 'Fibroscore Study' in France. The effect of the various mutations on the rate of fi-brosis was analyzed statistically and was correlated with epidemiological, clinical and biochemical data such as grade and stage of liver biopsies, patients' risk factors for liver cirrhosis, and timing of infection. RESULTS: Fifty two of the patients were categorized as 'fast fi brosers' and 116 as 'slow fi brosers'; 13% of the 'fast fi brosers' carried the PT20210 mutation as compared with 5.5% of the 'slow fi brosers', with an odds ratio of 4.76 (P = 0.033; 95% CI: 1.13-19.99) for 'fast' liver fibrosis. Carriage of MTHFR or FV Leiden mutations was not associated with enhanced liver fi brosis. CONCLUSION: Carriage of the PT20210 mutation is related to an increased rate of liver fi brosis in HCV patients. 关键词：丙型肝炎病毒基因突变凝血酶原肝纤维化患者亚甲基四氢叶酸还原酶 MTHFR基因感染时间

相关文献

参考文献（22）
引证文献（2）
耦合文献（0）

参考文献(22)

引证文献(2)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Increased fibrosis progression rates in hepatitis C patients carrying the prothrombin G20210A mutation

参考文献(22)

引证文献(2)

用户提示